Tiziana Life Sciences Ltd

This early-stage study is testing whether a nasal spray called foralumab can reduce harmful brain inflammation and slow disease progression in people with multiple system atrophy (MSA), a rare and serious neurological disorder. The trial will enroll 5 patients to check the treatm…

This study is testing whether a new nasal spray called foralumab can slow the progression of disability in people with a specific form of multiple sclerosis (MS) that has stopped having active flare-ups. It will involve 54 patients who will use either a low dose, a high dose, or …